NASDAQ
Capricor Therapeutics, Inc. (CAPR)
♥ 334 Thanks from members
Capricor Therapeutics (CAPR) displays extreme binary volatility driven by conflicting FDA advisory panel doubts on deramiocel's cardiomyopathy efficacy versus peer-reviewed Lancet validation of its 54% upper-limb decline slowing, drawing intense trader interest ahead of the August 22, 2026 PDUFA action date.